热门资讯> 正文
Biomea Fusion在临床搁置后在巴克莱银行裁员
2024-06-07 20:59
- Barclays has downgraded Biomea Fusion (NASDAQ:BMEA) to equal weight from overweight citing the June 6 announcement that the U.S. FDA placed a full clinical hold on phase 1/2 trials for BMF-219 for type 1 and type 2 diabetes.
- The firm also lowered its price target to $5 from $30 (~56% downside based on Thursday's close).
- Analyst Peter Lawson said the downgrade is being done until there is resolution on the hold, which was caused by potential drug-induced liver toxicity.
- Despite the setback, he expects initial expansion data from the type 3 trial, COVALENT-111, in the second half of the year as well as phase 2 data in from the open-label portion of the type 1 COVALENT-112 trial by the end of the year as well.
More on Biomea Fusion
- Biomea stock plunges 62% after hours on FDA clinical hold
- Biomea Fusion drops as JPMorgan downgrades on data for lead asset
- Seeking Alpha’s Quant Rating on Biomea Fusion
- Historical earnings data for Biomea Fusion
- Financial information for Biomea Fusion
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
